GlaxoSmithKline’s asthma drug Nucala may not be on the same tier as rival Regeneron’s Dupixent, but it has scored a speedy review for use in a rare blood disorder.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,